SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.…
SpectraCure aktie 2026/2027: starkt sälj – kurs och analys
SpectraCure (STO: SPEC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.0136 SEK on 20 November 2026, down 93.1% over 52 weeks. Its 52-week range is 0.0100 SEK to 0.2120 SEK: the price is 93.6% below the high and 36.0% above the low.
Its market capitalisation is 10.00M SEK.
SpectraCure reports return on equity of -59.9%.
Its debt exceeds its cash by 1.28M SEK, a debt-to-equity ratio of 0.03. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.